RUNX1::RUNX1T1 (AML1::ETO) t(8;21) Detection, Quantitative
Also known as: AML1-ETO Q
Use
This test is used to detect and quantify RUNX1::RUNX1T1 (AML1::ETO) fusion transcripts resulting from t(8;21), a recurrent genetic abnormality found in a subset of acute myeloid leukemia patients. It is beneficial for monitoring minimal residual disease and assessing the risk of relapse, aiding in the clinical management of patients diagnosed with this condition.
Special Instructions
Specimens must be received within 48 hours of collection due to RNA lability. Separate specimens are required when multiple tests are ordered. Ensure specimens are critically refrigerated and transported correctly to avoid rejection.
Limitations
Translocations involving other genes or gene partners will not be detected. The limit of detection for this test is 1 in 100,000. Results should be interpreted within the clinical context of the patient and in conjunction with other relevant data. This test should not be used solely for diagnosing malignancy.
New York Approved
Methodology
PCR-based (RT-PCR)
Biomarkers
LOINC Codes
- 21819-8
- 21793-5
- 21821-4
Result Turnaround Time
5-9 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
5 mL
Minimum Volume
3 mL
Container
Lavender (EDTA)
Storage Instructions
Refrigerate immediately.
Causes for Rejection
Serum, plasma, extracted DNA, CSF, FFPE tissue, ambient or frozen whole blood or bone marrow, and specimens in non-EDTA anticoagulants. Severely hemolyzed or clotted specimens and ambient bone marrow past 7 days.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Unacceptable |
| Refrigerated | 48 hours |
| Frozen | Unacceptable |